Logo

Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

Share this

Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

Shots:

  • The approval is based on the results of P-III MURANO study assessing Venclexta + MabThera (six cycles) vs (bendamustine + MabThera) (BR) (six cycles) in 389 patients in ratio (1:1) with 1L r/r CLL for two years
  • P-III MURANO study results: mPFS 83%; no. of events (32 vs 114); ORR (93.3% vs 67.7%); CR/CRi (26.8% vs 8.2%); MRD-negativity in peripheral blood- bone marrow (62.5%- 15.5% vs 13.3%-1.0%)
  • Venclyxto is a novel inhibitor of B-cell lymphoma-2 (BCL-2) protein- developed by Roche & AbbVie and is currently approved in 50 countries

Ref: Roche | Image: Roche


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions